This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.
Full Title of Study: “A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency”
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Prevention
- Masking: None (Open Label)
- Drug: Primaquine
Clinical Trial Outcome Measures
- Difference in degree of hemolysis of G6PD(-) red blood cells in treated vs untreated matched samples.
Participating in This Clinical Trial
- Normal clinical evaluation – Willing and able to make all scheduled visits Exclusion: – pregnant or planning pregnancy – Have taken any anti-malarial medication in past month – Positive blood tests for HIV and specific types of hepatitis – Allergic to primaquine
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 60 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- Walter Reed Army Institute of Research (WRAIR)
- Overall Official(s)
- Shon A Remich, Principal Investigator, WRAIR, Experimental Therapeutics
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.